Trastuzumab Deruxtecan is a biopharmaceutical product produced by living cell expression systems, whose pharmacological activity arises from specific binding interactions with biological targets including cell-surface receptors, soluble cytokines, or enzyme active sites. The manufacturing process—encompassing upstream cell culture, downstream purification, and formulation—is intrinsically linked to product quality and must be validated to ensure consistent structure and potency. PDE assessment for biological compounds focuses on on-target pharmacological hazard, with occupational inhalation exposure to protein aerosols during fill-finish operations representing the primary manufacturing exposure concern.
Reproductive and developmental toxicity findings for Trastuzumab Deruxtecan receive an additional severity factor consideration in PDE derivation, because pharmaceutical patient populations frequently include women of childbearing potential and, in some indications, pregnant patients.
